(Q38872239)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

review article

1 reference

title

Anti-angiogenic agents in ovarian cancer: past, present, and future (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

angiogenesis inhibitor

1 reference

B J Monk

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

L E Minion

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

R L Coleman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

1 April 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

27 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

i33-i39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

Latest research and treatment of advanced-stage epithelial ovarian cancer

3 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

VEGF inhibition, hypertension, and renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an explora

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Incorporation of pazopanib in maintenance therapy of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

Incidence and management of edema associated with trebananib (AMG 386).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW093

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

21 January 2018

1 reference

12 December 2020

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

12 December 2020

Value-Based Cancer Care

1 reference

12 December 2020

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

1 reference

12 December 2020

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

1 reference

12 December 2020

State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer

1 reference

12 December 2020

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

12 December 2020

Identifiers

DOI

10.1093/ANNONC/MDW093

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141068%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PubMed publication ID

27141068

1 reference